Scientists who conducted a randomised, double-blind, placebo-controlled, phase III study, evaluating siponimod versus a placebo in patients with secondary progressive multiple sclerosis (SPMS) have managed to reduce the risk of disability progression by 21 per cent, over a three month period.
Overall, 1,651 patients were randomised. siponimod reduced the risk of confirmed disability progression (CDP) by 21 per cent, versus the placebo. This was assessed using the Expanded Disability Status Scale (EDSS). The risk reduction observed in a Timed 25-Foot Walk test was 6.2 per cent and not statistically significant.
However, risk reduction increased to 26 per cent over a six-month period of CPD. This reveals that siponimod had a positive effect on disability progression in SPMS. The findings indicated that the longer a patient takes siponimod, the longer they could stave off disability progression. However, more trials are needed to clarify its full capabilities.
Surce: MS-UK (09/05/17)